Jose P Zevallos1, Nandita Mitra2, Samuel Swisher-McClure3. 1. Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 2. Department of Biostatistics and Epidemiology, Leonard Davis Institute of Health Economics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Radiation Oncology, Leonard Davis Institute of Health Economics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Transoral endoscopic surgery is a promising new treatment for oropharyngeal squamous cell carcinoma (SCC). METHODS: We examined care patterns and outcomes in 514 patients with oropharyngeal SCC undergoing transoral endoscopic surgery within the 2010 to 2011 National Cancer Database (NCDB). RESULTS: Most patients had T1 to T2 tumors (88.5%), and were treated in academic facilities (64.2%). Mean length of hospitalization was 5.1 days and perioperative mortality was 0.8%. Final surgical margins were positive in 20% of patients, and were more common with T2 (odds ratio [OR] = 2.35; p < .05) or N2 disease (OR = 4.18; p < .001), treatment in community cancer centers (OR = 1.81; p < .05), and low volume centers (OR = 2.43; p < .05). CONCLUSION: Early adoption of transoral surgery for oropharyngeal SCC had an excellent safety profile. We observed higher rates of positive surgical margins than previously reported. These findings highlight the importance of surgeon experience and patient selection, and suggest that transoral endoscopic surgery for oropharyngeal SCC be performed by highly trained surgeons in the context of multidisciplinary care.
BACKGROUND: Transoral endoscopic surgery is a promising new treatment for oropharyngeal squamous cell carcinoma (SCC). METHODS: We examined care patterns and outcomes in 514 patients with oropharyngeal SCC undergoing transoral endoscopic surgery within the 2010 to 2011 National Cancer Database (NCDB). RESULTS: Most patients had T1 to T2 tumors (88.5%), and were treated in academic facilities (64.2%). Mean length of hospitalization was 5.1 days and perioperative mortality was 0.8%. Final surgical margins were positive in 20% of patients, and were more common with T2 (odds ratio [OR] = 2.35; p < .05) or N2 disease (OR = 4.18; p < .001), treatment in community cancer centers (OR = 1.81; p < .05), and low volume centers (OR = 2.43; p < .05). CONCLUSION: Early adoption of transoral surgery for oropharyngeal SCC had an excellent safety profile. We observed higher rates of positive surgical margins than previously reported. These findings highlight the importance of surgeon experience and patient selection, and suggest that transoral endoscopic surgery for oropharyngeal SCC be performed by highly trained surgeons in the context of multidisciplinary care.
Authors: Peter W Kahng; Xiaotian Wu; Nithya P Ramesh; David A Pastel; Ryan J Halter; Joseph A Paydarfar Journal: Int J Comput Assist Radiol Surg Date: 2019-02-07 Impact factor: 2.924
Authors: Nitin A Pagedar; Catherine Chioreso; Jennifer A Schlichting; Charles F Lynch; Mary E Charlton Journal: Cancer Causes Control Date: 2017-08-16 Impact factor: 2.506
Authors: Anna B Beckmeyer-Borowko; Caryn E Peterson; Katherine C Brewer; Mary A Otoo; Faith G Davis; Kent F Hoskins; Charlotte E Joslin Journal: Cancer Causes Control Date: 2016-09-02 Impact factor: 2.506
Authors: Andrew J Holcomb; Rachael Kammer; Allison Holman; Tessa Goldsmith; Vasu Divi; Heather M Starmer; Joseph Zenga; Ryan Li; Urjeet A Patel; Jeremy D Richmon Journal: J Robot Surg Date: 2022-08-07
Authors: Anthony T Nguyen; Michael Luu; Jon Mallen-St Clair; Alain C Mita; Kevin S Scher; Diana J Lu; Stephen L Shiao; Allen S Ho; Zachary S Zumsteg Journal: JAMA Oncol Date: 2020-10-01 Impact factor: 31.777
Authors: Robert L Ferris; Yael Flamand; F Christopher Holsinger; Gregory S Weinstein; Harry Quon; Ranee Mehra; Joaquin J Garcia; Michael L Hinni; Neil D Gross; Erich M Sturgis; Umamaheswar Duvvuri; Eduardo Méndez; John A Ridge; J Scott Magnuson; Kerry A Higgins; Mihir R Patel; Russel B Smith; Daniel W Karakla; Michael E Kupferman; James P Malone; Benjamin L Judson; Jeremy Richmon; Jay O Boyle; Rodrigo Bayon; Bert W O'Malley; Enver Ozer; Giovana R Thomas; Wayne M Koch; R Bryan Bell; Nabil F Saba; Shuli Li; Elin R Sigurdson; Barbara Burtness Journal: Oral Oncol Date: 2020-07-14 Impact factor: 5.337